Reuters logo
BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial
December 6, 2017 / 11:59 AM / in 6 days

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

Dec 6 (Reuters) - Madrigal Pharmaceuticals Inc:

* MADRIGAL‘S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

* MADRIGAL PHARMACEUTICALS INC - MGL-3196 HAS BEEN WELL-TOLERATED WITH MOSTLY MILD AES, AND A FEW MODERATE AES IN STUDY

* MADRIGAL PHARMACEUTICALS INC - THERE HAVE BEEN THREE SERIOUS ADVERSE EFFECTS IN STUDY, ALL CONSIDERED UNRELATED TO MGL-3196

* MADRIGAL PHARMACEUTICALS - IN TRIAL, MGL-3196 DEMONSTRATED STATISTICALLY SIGNIFICANT RESULTS FOR THE PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below